January 24, 2020 07: 09 AM EST
Amber Tong
FDA waves Epizyme’s $186 K rare cancer drug through to market– now prepare yourself for the 2nd act
Robert Bazemore
” Epithelioid sarcoma accounts for less than one percent of all soft tissue sarcomas,” Richard Pazdur, the powerful director of the FDA’s Oncology Center of Quality, mentioned.
Shefali Agarwal
SPONSORED
January20,
202007:00 AM EST
Blue Latitude Health
January24,202010:24 AM EST
John Carroll
Aymeric Le Chatelier, Ipsen
January24,
202008:30 AM EST Updated09:
17AM
John Carroll
.
A$ 1B-plus drug stumbles into another huge PhIII problem– this time failing futility test– as FDA hold stays in effect for Ipsen
.
David Meek
.
At the time Ipsen stepped up in 2015 with more than a billion dollars in cash to purchase Clementia and a late-stage program for a rare bone illness that afflicts children, then CEO David Meek was confident that he had actually put the French biotech on a short path to a mid-2020 launch.
.
Instead of prepping a launch, however, the company was hit with a hold on the FDA’s issues that a treatment designed to prevent overgrowth of bone for cases of fibrodysplasia ossificans progressiva might in fact stunt kids’s growth.
So they ordered a stop to any treatments for kids14 and under. Meek left soon
after to run a start-up in Boston. And today the Paris-based biotech is grappling with the independent tracking committee’s choice that their Phase III had stopped working a futility test.
Keep reading Endpoints with a free subscription
Open this story instantly and sign up with70,400 biopharma pros checking out Endpoints daily–
and it’s totally free.
.
Alex Karnal( Deerfield)
.
January24,202009:53 AM EST
Amber Tong
Back at the beginning of 2015, Deerfield Management co-led a $10 million Series C for a personal gene treatment startup, reshaping the company and bringing in new leaders to pave method for an IPO simply a year later on.
.
January24,202009: 38 AM EST Upgraded10:00 AM
Natalie Grover
Various healing traits brandished by the 3 authorized treatments for sickle cell illness all extend life span, but their effect on lifestyle doubts and their long-lasting cost-effectiveness is not up to scratch according to the limits thought about reasonable by ICER, the non-profit concluded in a draft assistance report on Thursday.
Sickle cell disease( SCD ), which includes a group of inherited red blood cell disorders that usually affect those of African ancestry, impacts hemoglobin– and is identified by episodes of searing discomfort in addition to organ damage.
.
.
January 24, 202006:
17 AM EST Upgraded06:42 AM
Natalie Grover
.
Roche’s checkpoint player Tecentriq flops in another bladder cancer subset
Simply weeks after Merck’s star checkpoint inhibitor Keytruda secured FDA approval for a subset of bladder cancer clients, Swiss rival
Roche’s Tecentriq has failed in a pivotal bladder
cancer research study.
The 809- patient trial– IMvigor010– evaluated the PD-L1 drug in clients with muscle-invasive urothelial cancer (MIUC) who had actually undergone surgery, and were at high risk for recurrence.
.
Keep checking out Endpoints with a free membership
Open this story instantly and join70,400 biopharma pros reading Endpoints
daily– and it
‘s free.
January23,202010: 32 AM ESTUpgraded01:52 PM
John Carroll
UPGRADED: Eli Lilly’s $1.6 B cancer drug failed to spark even the tiniest favorable gain for patients in its first PhIII
Eli Lilly had high wish for its pegylated IL- 10 drug pegilodecakin when it bought Armo in 2015 for$ 1.6 billion in money But after reporting a few months ago that it had failed a Stage III in pancreatic cancer, without the data, its most likely value has plunged. And now we’re getting some precise information that underscore simply how little positive effect it had.
Keep checking out Endpoints with a complimentary subscription
Unlock this story immediately and sign up with70, 400 biopharma pros checking out Endpoints daily– and it’s totally free.
January22,202006:04 AM EST Updated11:06 AM
John Carroll
Keep reading Endpoints with a free subscription
.
source https://jobsearchtips.net/fda-waves-epizymes-186k-unusual-cancer-drug-through-to-market-now-prepare-for-the-2nd-act/
No comments:
Post a Comment